Author:
Shoaf Susan E.,Bricmont Patricia,Dandurand Ann
Funder
Otsuka Pharmaceutical Development & Commercialization, Inc.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference14 articles.
1. Samsca [Package Insert]. Rockville, MD: Otsuka America Pharmaceuticals, Inc.; 2014
2. European Medicines Agency. Samsca: Summary of Product Characteristics (Annex I). [September 2016]; Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000980/human_med_001046.jsp&mid=WC0b01ac058001d124
3. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T (2007) Tolvaptan, an orally active vasopressin V(2)-receptor antagonist—pharmacology and clinical trials. Cardiovasc Drug Rev 25(1):1–13
4. Schrier RW, Gross P, Gheorghiade M et al (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355(20):2099–2112
5. Verbalis JG, Adler S, Schrier RW et al (2011) Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 164(5):725–732
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献